Lineage Cell Therapeutics Inc. (NYSE AMERICAN: LCTX)
$1.03
-0.0400 ( -3.74% ) 213.6K
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Market Data
Open
$1.03
Previous close
$1.07
Volume
213.6K
Market cap
$194.49M
Day range
$1.02 - $1.07
52 week range
$0.84 - $1.61
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | May 14, 2024 |
8-k | 8K-related | 13 | May 09, 2024 |
10-q | Quarterly Reports | 76 | May 09, 2024 |
ars | Annual reports | 1 | Apr 29, 2024 |
def | Proxies and info statements | 6 | Apr 29, 2024 |
8-k | 8K-related | 14 | Mar 22, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |
10-k | Annual reports | 116 | Mar 07, 2024 |